China-based VFLO Medical, a peripheral vascular device firm incubated by 6 Dimensions Capital, has announced a strategic partnership with US firm Inari Medical, Inc. (NASDAQ: NARI). The deal will enable Inari to leverage VFLO’s established infrastructure, local relationships, and deep commercial expertise for the commercialization of its devices in Greater China. Additionally, VFLO will have the right to utilize Inari’s technology to manufacture products for domestic sale in the region.
VFLO Medical Closes USD 80 Million Series B Financing Round
In conjunction with the partnership, VFLO has announced the closing of a USD 80 million Series B financing round. The round was backed by 6 Dimensions Capital, its successor fund 120 Capital, a large family office, Hefei Industry Investment, Hefei High Tech Venture Capital, and USTC Innovation Valley, among others. The proceeds from this funding will be directed towards bolstering the clinical development and promotion of VFLO’s peripheral vascular pipelines.
Innovative Medical Devices with Global Impact
ClotTriever, an innovative mechanical thrombectomy device developed for deep vein thrombosis, received marketing approval from the US FDA in 2017. FlowTriever, the world’s first mechanical thrombus clearing system for the treatment of pulmonary embolism, was approved for marketing in the US in 2015. These products, awarded fast-track statuses as innovative medical devices in China, have treated more than 150,000 patients worldwide, highlighting their significant impact on patient care.-Fineline Info & Tech
